All In Biotech

Drug Trial Radar · NCT02476123

Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 11, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

118

Actual

Start

Jun 2015

Primary completion

Feb 7, 2018

Study completion Dec 21, 2018

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Ono Pharmaceutical Co., Ltd.
First posted
Jun 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of Mogamulizumab and Nivolumab in subjects with locally advanced or metastatic solid tumors.

Conditions

  • Solid Tumor

Interventions

  • Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)Biological

    i.v. administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects reporting adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
  2. Number of subjects reporting serious adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
  3. Percentage of subjects reporting serious adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
  4. Percentage of subjects reporting adverse eventsTime frame: From the first dose of study medications until 90 days after the last dose of study medication
  5. Number of subjects experiencing dose-limiting toxicityTime frame: For 28 days from the first dose of study medications

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Chiba, Japan

  • Site not named

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.